Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.
about
Pharmacokinetic-pharmacodynamic relationship of anesthetic drugs: from modeling to clinical useCurrent advances in mathematical modeling of anti-cancer drug penetration into tumor tissuesUnderstanding and applying pharmacometric modelling and simulation in clinical practice and researchVisualization and communication of pharmacometric models with berkeley madonnaModeling and simulation of count data.Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic ReviewPopulation Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response.Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensPopulation pharmacokinetics of gentamicin and dosing optimization for infantsPopulation pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRIPopulation pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenDesigning More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationExternal evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenPopulation Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.Noncompetitive Inhibition of 5-HT3 Receptors by Citral, Linalool, and Eucalyptol Revealed by Nonlinear Mixed-Effects Modeling.Dosage individualization in children: integration of pharmacometrics in clinical practice.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsPopulation Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.Optimizing drug development in oncology by clinical trial simulation: Why and how?Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.Population Pharmacokinetics of Amoxicillin in Term Neonates Undergoing Moderate Hypothermia.A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study.Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.
P2860
Q26766216-18CD4403-BAC7-4DB8-A822-E48A5E0152C7Q26827129-0260D0AA-9296-4671-8FF6-F694E1ACAED0Q28468334-4F500976-8AAD-4235-BDCD-759E2725D679Q29584444-866711DF-CD34-4ADD-B828-7C3CF53E506EQ30842267-3C0E0E9F-828A-40B6-B6FF-A60E2E3A5B06Q33658786-455FC56D-7A59-4DBB-ACBF-2FA15EF12145Q33729768-949635E7-EB15-4F2B-B8C3-BFEEC08BCCB1Q33887993-E2316935-3227-4D0C-A14E-458CEDA913F9Q33891532-64970797-744A-49B3-BC70-4EA1EB56C0AEQ34058346-73BBD773-7EF9-4C25-BA84-AD33DB50F092Q34554423-7F075CE8-299C-46F0-8D7F-0DCE749D6289Q34570886-BBF6692A-3484-43B5-B7C2-C020411CDF02Q34923469-69990115-595F-4AC1-A7FE-561A64EAAE3BQ34953673-AE4E4B39-914C-4421-A0DF-104C45323EECQ35903844-97E81071-0476-4C69-9C8E-EFD241C6D06EQ35960882-4154B537-F029-4C56-A60B-D4D816B56A0FQ36203402-A47AF03F-47CF-4CBB-8C1D-8B9B1D531FFDQ36322918-AEA5CC27-3EFD-4AF6-8041-D63F63463C4AQ36618085-E0A5DF04-4F1F-4CC8-B3BD-28CB5792387EQ36734132-8C9D74A3-C8C7-4ABA-B510-E54A99968222Q36806621-06853667-4416-4B41-A564-0873B1BE98DBQ36888137-1E8F5B0F-56E1-43B6-A5FA-8EA849499F71Q36924742-5F3F8C4C-726E-4924-AA54-A4F8821172E9Q37030715-ACD62236-BFA4-4372-8F96-1C33DABB47C6Q37538698-659620A9-7E75-4AC4-A406-78107954FAC0Q37540180-2D01B82E-0737-4609-AC3B-D9A86977DEA2Q37736269-EEA7E4EB-E842-4FFA-BD73-F1930416E223Q38240055-C0245321-E95A-4871-A5ED-3373DB76BD0AQ38540353-8C97A32B-FF0C-4966-A651-159E847A3A6EQ38557331-9EEDA834-D8B1-46B1-A319-92FAABAA624EQ38674724-6C12824C-7367-4C5C-A25E-9B3CDBECBD4EQ38675644-06C5812F-1956-426C-B2B6-89183DAF1471Q38703261-9A04902E-EA4B-4939-B855-358FE07A0620Q38714060-558AC046-E2D5-451D-854B-AA735256A46CQ38729024-10C8F505-B940-4A03-81BD-D37D08C3238DQ38757638-CC980D88-9A02-4FD5-A422-3A8235F9FFC7Q38765917-3BEDC11D-B98B-40E5-8A75-DE0E97F54C73Q38790140-C51FAEF1-0EF9-472B-9155-7DF91B60B7EBQ38873556-A2FBD136-0AFF-47B8-9696-EDBA3E1F3140Q38931118-CEE8F61B-F8C2-4463-8FE2-90ED416218A3
P2860
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Basic concepts in population m ...... rmacokinetic modeling methods.
@en
type
label
Basic concepts in population m ...... rmacokinetic modeling methods.
@en
prefLabel
Basic concepts in population m ...... rmacokinetic modeling methods.
@en
P2860
P356
P1476
Basic concepts in population m ...... armacokinetic modeling methods
@en
P2093
P2860
P356
10.1038/PSP.2013.14
P577
2013-04-17T00:00:00Z